<VariationArchive VariationID="1065947" VariationName="NM_000090.4(COL3A1):c.648_665del (p.Pro218_Pro223del)" VariationType="Deletion" Accession="VCV001065947" Version="7" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-02" DateCreated="2021-05-10" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1055160" VariationID="1065947">
      <GeneList>
        <Gene Symbol="COL3A1" FullName="collagen type III alpha 1 chain" GeneID="1281" HGNC_ID="HGNC:2201" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2q32.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="188974373" stop="189012746" display_start="188974373" display_stop="189012746" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NW_025791764.1" start="79333" stop="117706" display_start="79333" display_stop="117706" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="189839098" stop="189877471" display_start="189839098" display_stop="189877471" Strand="+" />
          </Location>
          <OMIM>120180</OMIM>
          <Haploinsufficiency last_evaluated="2017-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL3A1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2017-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL3A1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000090.4(COL3A1):c.648_665del (p.Pro218_Pro223del)</Name>
      <CanonicalSPDI>NC_000002.12:188989403:AGGACCTCCTGGTGCTATAGG:AGG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2q32.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="188989404" stop="188989421" display_start="188989404" display_stop="188989421" variantLength="18" positionVCF="188989403" referenceAlleleVCF="CAGGACCTCCTGGTGCTAT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="189854130" stop="189854147" display_start="189854130" display_stop="189854147" variantLength="18" positionVCF="189854129" referenceAlleleVCF="CAGGACCTCCTGGTGCTAT" alternateAlleleVCF="C" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.189854133_189854150del" Assembly="GRCh37">
            <Expression>NC_000002.11:g.189854133_189854150del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.188989407_188989424del" Assembly="GRCh38">
            <Expression>NC_000002.12:g.188989407_188989424del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007404.1" sequenceAccession="NG_007404" sequenceVersion="1" change="g.20035_20052del">
            <Expression>NG_007404.1:g.20035_20052del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000090.4" sequenceAccession="NM_000090" sequenceVersion="4" change="c.648_665del" MANESelect="true">
            <Expression>NM_000090.4:c.648_665del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000081.2" sequenceAccession="NP_000081" sequenceVersion="2" change="p.Pro218_Pro223del">
            <Expression>NP_000081.2:p.Pro218_Pro223del</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001822" Type="inframe_deletion" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_3" sequenceAccession="LRG_3">
            <Expression>LRG_3:g.20035_20052del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2153501869" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000090.4(COL3A1):c.648_665del (p.Pro218_Pro223del) AND Ehlers-Danlos syndrome, type 4" Accession="RCV001376803" Version="6">
        <ClassifiedConditionList TraitSetID="6334">
          <ClassifiedCondition DB="MedGen" ID="C0268338">Ehlers-Danlos syndrome, type 4</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-07-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-07-14" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-05-10" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19344236</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22492385</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24399159</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24922459</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25758994</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30474650</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30793832</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7695699</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8218237</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-11">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="6334" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1585" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos syndrome vascular type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, ecchymotic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, arterial type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, Sack-Barabas type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ehlers-Danlos syndrome, type 4</ElementValue>
                <XRef ID="Ehlers-Danlos+Syndrome+Vascular+Type/2491" DB="Genetic Alliance" />
                <XRef ID="17025000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos Syndrome Type IV</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">EDS IV</ElementValue>
                <XRef Type="MIM" ID="130050" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EDS4</ElementValue>
                <XRef Type="MIM" ID="130050" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Vascular Ehlers-Danlos syndrome (vEDS) is characterized by arterial, intestinal, and/or uterine fragility; thin, translucent skin; easy bruising; characteristic facial appearance (thin vermilion of the lips, micrognathia, narrow nose, prominent eyes); and an aged appearance to the extremities, particularly the hands. Vascular dissection or rupture, gastrointestinal perforation, or organ rupture are the presenting signs in most adults with vEDS. Arterial rupture may be preceded by aneurysm, arteriovenous fistulae, or dissection but also may occur spontaneously. The majority (60%) of individuals with vEDS who are diagnosed before age 18 years are identified because of a positive family history. Neonates may present with clubfoot, hip dislocation, limb deficiency, and/or amniotic bands. Approximately half of children tested for vEDS in the absence of a positive family history present with a major complication at an average age of 11 years. Four minor diagnostic features – distal joint hypermobility, easy bruising, thin skin, and clubfeet – are most often present in those children ascertained without a major complication.</Attribute>
                <XRef ID="NBK1494" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2082" />
                <XRef ID="2082" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301667</ID>
                <ID Source="BookShelf">NBK1494</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2010">
                <ID Source="pmc">2987428</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2013">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_Ehlers-DanlosTypeIV-enPro4042.pdf</URL>
                <CitationText>Orphanet Emergency Guidelines: Type IV Ehlers-Danlos Syndrome</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="CCS, 2014">
                <ID Source="PubMed">24882528</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173340</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="CSANZ, 2017">
                <ID Source="PubMed">28161018</ID>
              </Citation>
              <XRef ID="286" DB="Orphanet" />
              <XRef ID="C0268338" DB="MedGen" />
              <XRef ID="MONDO:0017314" DB="MONDO" />
              <XRef Type="MIM" ID="130050" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3099565" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="4502397|MedGen:C0268338" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001573974" DateUpdated="2024-02-14" DateCreated="2021-05-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">7695699</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8218237</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19344236</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24922459</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25758994</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22492385</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24399159</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30474650</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30793832</ID>
          </Citation>
          <Comment>ClinVar contains an entry for this variant (Variation ID: 1065947). This variant disrupts the triple helix domain of COL3A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL3A1, variants that affect these glycine residues are significantly enriched in individuals with disease (PMID: 24922459, 25758994) compared to the general population (ExAC). This variant disrupts a region of the COL3A1 protein in which other variant(s) (p.Gly222Arg) have been determined to be pathogenic (PMID: 22492385, 24399159, 30474650, 30793832). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. This variant, c.648_665del, results in the deletion of 6 amino acid(s) of the COL3A1 protein (p.Pro218_Pro223del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with COL3A1-related conditions.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL3A1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.189854130_189854147del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268338" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3099565" TraitType="Disease" MappingType="XRef" MappingValue="C0268338" MappingRef="MedGen">
        <MedGen CUI="C0268338" Name="Ehlers-Danlos syndrome, type 4" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

